Member Info for Jarv55

https://www.lse.co.uk/rns/MPH/mereo-biopharma-grp-holdings-in-company-wgp9l652lou16ym.html
https://www.lse.co.uk/rns/MPH/holdings-in-company-7d8zadz9r6w73d1.html
https://www.lse.co.uk/rns/MPH/holdings-in-company-5aadaybuydlka4g.html
https://www.lse.co.uk/rns/MPH/notification-of-major-holdings-in-company-waa27kjxa5gki7s.html
https://www.lse.co.uk/rns/MPH/notification-of-holdings-in-company-pkxwdscviz3dgz7.html

Because that looks to me that they were transferred to Link and Schroders

donmac which fund was Mph in?
https://citywire.co.uk/funds-insider/news/link-boss-disputes-woodford-hysteria-and-downplays-fine-risk/a1294676
https://www.ft.com/content/6e8e2e26-f627-11e9-a79c-bc9acae3b654

Maybe Woody overhang finally cleared or a second seller is out?

Watch this https://www.youtube.com/watch?v=0-xMoqm8nhk

https://www.proactiveinvestors.co.uk/companies/news/906875/astrazeneca-and-the-art-of-resurrecting-failed-drug-candidates-906875.html

https://pharmaphorum.com/news/mereos-brittle-bone-drug-likely-to-shrug-off-phase-2b-fail-say-analysts/

http://capita.moneyam.com/broker-views/MPH/Mereo-Biopharma-Group.html

The 52 week high was 1.80

https://stockhouse.com/companies/insiders?symbol=mreo

https://stockhouse.com/companies/quote?symbol=mreo mc 57mc

London, 23 April 2019 - Mereo BioPharma Group plc (AIM: MPH), a clinical stage, UK-based, biopharmaceutical company focused on rare diseases, announces that the merger with OncoMed Pharmaceuticals, Inc. ("OncoMed" NASDAQ:OMED) announced on 5 December 2018 has today completed.



This follows the approval from the stockholders of OncoMed on 17 April 2019 of the transactions contemplated by the merger agreement dated 5 December 2018 (the "Merger") between Mereo, OncoMed and certain other parties thereto (the "Merger Agreement"), and OncoMed has today become a wholly-owned indirect subsidiary of Mereo following the effective filing of a certificate of merger with the Secretary of State of the State of Delaware. In connection with completion of the Merger:



· Mereo has today issued 24,783,320 new ordinary shares (the "New Shares") to Citibank, N.A., London Branch, as custodian, and will instruct Citibank, N.A., as depositary, to deliver 4,956,664 American Depositary Shares (the "ADSs") to former OncoMed stockholders, each ADS representing five New Shares. The ADSs are expected to be admitted to trading on the Global Market of Nasdaq Stock Exchange Market LLC on 24 April 2019, under the ticker symbol "MREO"; and

07 October 2019




Mereo BioPharma Receives FDA Fast Track Designation for Navicixizumab for the Treatment of Heavily Pretreated Ovarian Cancer



London and Redwood City, Calif., October 7, 2019 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company" or the "Group," a clinical stage biopharmaceutical company focused on rare diseases, today announces that the U.S. Food and Drug Administration ("FDA") has granted Fast Track designation to navicixizumab for the treatment of high grade ovarian, primary peritoneal or fallopian tube cancer in patients who have received at least 3 prior therapies and/or prior bevacizumab. Navicixizumab is an anti-DLL4/VEGF bispecific antibody and one of two product candidates Mereo acquired through its April 2019 merger with OncoMed Pharmaceuticals, Inc.



"We are pleased that the FDA continues to recognize the potential of navicixizumab to become a viable new treatment option for patients with platinum-resistant ovarian cancer who failed multiple other therapies," said Jill Henrich, Senior Vice President of Regulatory Affairs at Mereo BioPharma. "This designation follows our successful Type B End of Phase 1 meeting with the FDA held in July 2019 regarding a potential pathway for accelerated approval for navicixizumab where the FDA agreed in principle on an outline for a Phase 2 clinical trial that could potentially support accelerated approval of navicixizumab in patients with ovarian cancer who have become resistant to prior therapies."



Navicixizumab has completed a Phase 1a monotherapy study in patients with various types of refractory solid tumors and is currently being evaluated in an ongoing Phase 1b study in combination with paclitaxel in patients with advanced heavily pretreated ovarian cancer. In line with the Company's strategy, a range of strategic partnering discussions have been initiated to provide additional funding for the navicixizumab program.

Navicixizumab has completed a Phase 1a single-agent clinical trial in patients with advanced solid tumors and is currently in a Phase 1b trial in combination with a standard paclitaxel regimen in patients with platinum-resistant ovarian cancer. This study recently completed enrolment; and

· Etigilimab has completed a single-agent Phase 1a trial in patients with advanced or metastatic solid tumors and is currently in a Phase 1b combination study with nivolumab. Etigilimab is part of OncoMed's prior collaboration with Celgene. Celgene has the option to obtain an exclusive licence to develop and commercialize the product. If Celgene exercises such option, OncoMed (now a wholly-owned indirect subsidiary of Mereo) will be eligible to receive a $35 million opt in payment.

https://www.youtube.com/watch?v=2xGIkc2HFd4&feature=youtu.be

This has been battered down due to the Woodford fund read the presentation they are in ongoing talks for partners

cottoner
10 Aug '19 - 19:00 - 20 of 76
0 1 0
Extract from todays Times Market Report.

Among the smaller stocks, Mereo Biopharma, a pharmaceuticals company that focuses on developing treatments for patients with rare diseases, rose by more than 7 per cent after Cantor Fitzgerald issued a “buy” rating on the stock and a target price of 720p, citing the value-adding potential of its respiratory therapies. The shares closed up 3p, or 7.1 per cent, at 45½p.

https://www.mereobiopharma.com/partners/current-partnerships/

Marty lol its Saturday tomorrow

The sp is building up strength to push through the 100ma and break out of the bull flag. Might take a few sessions but its looking good. https://invst.ly/p9cvu

While the placing price is low its been worth it if no further dilution occurs Uog have 4 drills next year at present a 12mc now compare that to say 88e same amount of shares in issue after dilution and a 77mill mc think Uog have a bit of catching up to do. Instis will start building stakes here think of the contacts they have from working with Tullow. Value investing at its finest buy low sit back and watch your pf grow honestly think its a good share for a Sipp. It's not going to rise a 100% in a day but can see a nice steady rise over the next year.